OS Therapies gears up for FDA meeting on cancer drug
NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into ...
manilatimes2d
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
Alphamab Oncology (stock code: 9966.HK) announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-306) of anti-HER2 biparatopic antibody-drug ...
verywellhealth3d
10 Tips for Living With Early-Stage HER2-Positive Breast Cancer
HER2-positive (HER2+) breast cancer treatments come with a range of unpleasant side effects. However, there are strategies ...
IFLScience3d
Plants Have Given Us Crucial Lifesaving Drugs – And Now We Risk Losing Them
These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...
Hosted on MSN3d
9 Healthy Diet Tips for HER2-Negative Metastatic Breast Cancer
Medically reviewed by Archana Sharma, DO Eating well can help support your immune system and maintain strength and energy if ...